These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17350840)

  • 21. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers.
    Fluxe A; Wu S; Sheffer JB; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Djandjighian L
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5855-8. PubMed ID: 16942878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches.
    Pirard B; Brendel J; Peukert S
    J Chem Inf Model; 2005; 45(2):477-85. PubMed ID: 15807513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach.
    Kajanus J; Jacobson I; Åstrand A; Olsson RI; Gran U; Björe A; Fjellström O; Davidsson Ö; Emtenäs H; Dahlén A; Löfberg B; Yuan ZQ; Sundell J; Cassel J; Gyll J; Iliefski T; Högberg Å; Lindhardt E; Malmberg J
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2023-9. PubMed ID: 26965854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.
    Olsson RI; Jacobson I; Boström J; Fex T; Björe A; Olsson C; Sundell J; Gran U; Öhrn A; Nordin A; Gyll J; Thorstensson M; Hayen A; Aplander K; Hidestål O; Jiang F; Linhardt G; Forsström E; Collins T; Sundqvist M; Lindhardt E; Åstrand A; Löfberg B
    Bioorg Med Chem Lett; 2013 Feb; 23(3):706-10. PubMed ID: 23260347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
    Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
    Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
    Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
    Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
    Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
    Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
    Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
    Finlay HJ; Jiang J; Caringal Y; Kover A; Conder ML; Xing D; Levesque P; Harper T; Hsueh MM; Atwal K; Blanar M; Wexler R; Lloyd J
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1743-7. PubMed ID: 23414837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
    Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
    Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
    Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
    J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
    Slack M; Kirchhoff C; Moller C; Winkler D; Netzer R
    J Biomol Screen; 2006 Feb; 11(1):57-64. PubMed ID: 16314404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
    Guo X; Ma X; Yang Q; Xu J; Huang L; Jia J; Shan J; Liu L; Chen W; Chu H; Wei J; Zhang X; Sun H; Tang Y; You Q
    Eur J Med Chem; 2014 Jun; 81():89-94. PubMed ID: 24824064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
    Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
    Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
    Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
    Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
    Beshore DC; Liverton NJ; McIntyre CJ; Claiborne CF; Libby B; Culberson JC; Salata JJ; Regan CP; Lynch JJ; Kiss L; Spencer RH; Kane SA; White RB; Yeh S; Hartman GD; Dinsmore CJ
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2493-6. PubMed ID: 20304642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology.
    Bilodeau MT; Trotter BW
    Curr Top Med Chem; 2009; 9(5):436-51. PubMed ID: 19519460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).
    Vaccaro W; Huynh T; Lloyd J; Atwal K; Finlay HJ; Levesque P; Conder ML; Jenkins-West T; Shi H; Sun L
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6381-5. PubMed ID: 19004630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
    Eldstrom J; Fedida D
    J Mol Graph Model; 2009 Oct; 28(3):226-35. PubMed ID: 19713139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
    Guo X; Chen W; Sun H; You Q
    Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.